Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer

Journal of Oncology Pharmacy Practice

Volumn 22, Issue 1, 2016, Pages 46-53

  Bicakli, Derya Hopanci ^a   Varol, Umut ^a   Degirmenci, Mustafa ^a   Tunali, Didem ^a   Cakar, Burcu ^a   Durusoy, Raika ^a   Karaca, Burcak ^a   Sanli, Ulus Ali ^a   Uslu, Ruchan ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Adjuvant chemotherapy; Breast cancer; Metabolic syndrome

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A1; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTRADIOL; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; PREALBUMIN; TRANSFERRIN; TRIACYLGLYCEROL; ANTINEOPLASTIC AGENT; TAXOID;

ADJUVANT THERAPY; ADULT; ALBUMIN BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEBRILE NEUTROPENIA; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; TRANSFERRIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO; WEIGHT CHANGE; WEIGHT GAIN; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; AGED; BREAST NEOPLASMS; CHEMICALLY INDUCED; RISK; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; METABOLIC SYNDROME X; MIDDLE AGED; RISK; TAXOIDS; TREATMENT OUTCOME;

EID: 84960887098     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155214551315     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics. Cancer J Clin 2010; 60: 277-300.
2. Honig SF. Hormonal therapy and chemotherapy. In: Harris JR, Lippman ME, Morrow M, Lippman ME and Hellman S (eds) Prognostic and predictive factors in diseases of the breast, 1st ed. Philadelphia, PA: Lippincott-Raven Publishers, 1996, pp.461-485.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005; 365: 1687-1717.
4. Kelly CM and Hortobagyi GN. Adjuvant chemotherapy in early-stage breast cancer: What, when, and for whom? Surg Oncol Clin N Am 2010; 19: 649-668.
5. Gajria D, Seidman A and Dang C. Adjuvant taxanes: More to the story. Clin Breast Cancer 2010; 2: 41-49.
6. Martin M, Pienkowski T, Mackey J, et al. Breast Cancer International Research Group 001 Investigators: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302-2313.
7. de Haas EC, Oosting SF, Lefrandt JD, et al. The metabolic syndrome in cancer survivors. Lancet Oncol 2010; 11: 193-203.
8. Rzymowska J. Effect of cytotoxic chemotherapy on serum lipid levels in breast cancer patients. Pathobiology 1999; 67: 129-132.
9. Subramaniam S, Marar T and Devi S. Studies on the changes in plasma lipids and lipoproteins in CMF treated breast cancer patients. Biochem Int 1991; 24: 1015-1024.
10. Kroenke CH, Chen WY, Rosner B, et al. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 2005; 23: 1370-1378.
11. Cowey S and Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J Pathology 2006; 169: 1505-1522.
12. Champ CE, Volek JS, Siglin J, et al. Weight gain, metabolic syndrome, and breast cancer recurrence: Are dietary recommendations supported by the data? Int J Breast Cancer 2012; 2012: 506868.
13. Keun HC, Sidhu J, Pchejetski D, et al. Serum molecular signatures of weight change during early breast cancer chemotherapy. Clin Cancer Res 2009; 15: 6716-6723.
14. Stebbing J, Sharma A, North B, et al. A metabolic phe-notyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. Ann Oncol 2012; 23: 860-866.
15. McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005; 96: 399-404.
16. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel detection, evaluation, and treatment of high blood cholesterol adults. (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486e97.
18. Alberti KG, Zimmet P and Shaw J. Metabolic syndrome - A new world-wide definition: A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
19. Despres JP and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
20. de Haas EC, Oosting SF, Lefrandt JD, et al. The metabolic syndrome in cancer survivors. Lancet Oncol 2010; 11: 193-203.
21. Redig AJ and Munshi HG. Metabolic syndrome after hormone-modifying therapy: Risks associated with anti-neoplastic therapy. Oncology 2010; 24: 839-844.
22. Nuver J, Smit AJ, Wolffenbuttel BH, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23: 3718-3725.
23. Tredan O, Bajard A, Meunier A, et al. Body weight change in women receiving adjuvant chemotherapy for breast cancer: A French prospective study. Clin Nutr 2010; 29: 187-191.
24. Ferre R, Aragones G, Plana N, et al. High-density lipo-protein cholesterol and apolipoprotein A1 levels strongly influence the reactivity of small peripheral arteries. Atherosclerosis 2011; 216: 115-119.
25. Majhail NS, Flowers ME, Ness KK, et al. High prevalence of metabolic syndrome after allogeneic hematopoi-etic cell transplantation. Bone Marrow Transplant 2009; 43: 49-54.
26. Demark-Wahnefried W, Peterson BL, Winer EP, et al. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2001; 19: 2381-2389.
27. Vehmanen L, Saarto T, Blomqvist C, et al. Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids. Br J Cancer 2004; 91: 476-481.
28. Nuver J, Smit AJ, van der Meer J, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 2005; 23: 9130-9137.
29. Kim JA, Montagnani M, Koh KK, et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888-1904.
30. Roos A, Bakker SJL, Links TP, et al. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 2007; 92: 491-496.